Ventures

Hemeo addresses the challenge of treating ICU patients with coagulation issues by developing a decision support system. This system uses patient data and real-time monitoring to accurately assess bleeding and thrombosis risks. By modeling the coagulation system with a smart algorithm, it provides personalized recommendations to clinicians, helping them make more informed therapy decisions. With ICU patients at high risk for venous thromboembolism and bleeding incidents, this solution aims to improve patient outcomes and reduce uncertainty in treatment.

MindAffect is redefining what’s possible in diagnostics. By harnessing Brain-Computer Interface technology and AI, we can “read” how the brain reacts to sound and visual stimuli—objectively, in real time, and without requiring a single response from the patient. At the core is our patented and clinically validated Rapid CAEP® technology, which captures the brain’s automatic reactions. This breakthrough allows clinicians to diagnose patients who would otherwise be difficult or impossible to test—such as infants, seniors, and individuals with disabilities. In a world where over two billion people are underserved by current diagnostic methods, this changes everything. Our first product, Sofi, is the world’s fastest objective hearing diagnostic system, delivering accurate hearing thresholds in minutes. Sofi has been validated in leading hospitals, championed by key opinion leaders across the audiology community, and recognized globally—winning the Innovation Award at the World Congress of Audiology

DiaphOne TX is developing a first-in-class, orally available small-molecule therapy targeting the RAGE/DIAPH1 pathway, a central but underexploited disease axis in chronic metabolic and inflammatory conditions including type 2 diabetes, obesity and MASH. While existing treatments manage symptoms, they fail to address underlying disease progression. DiaphOne TX's approach targets the root of metabolic stress, inflammation and fibrosis, in a single platform with applicability across multiple high-value, multi-billion-euro markets.

HapticHeart Solutions is revolutionizing cardiac procedures by giving cardiologists a "sense of touch" during catheter-based surgeries. These surgeries, which are becoming more complex, often require delicate maneuvers inside the heart. Their wearable device translates signals from the cath lab into tactile feedback, allowing cardiologists to feel what's happening inside the patient's heart. This helps them navigate catheters more effectively and focus on critical aspects of the procedure, leading to safer and more efficient surgeries with better outcomes for patients.

ArtiFex tackles a solution for coronary and peripheral bypass surgeries. Traditional grafts from the great saphenous vein face issues like rapid degeneration, leading to complications. With millions of bypass surgeries conducted annually and a billion-dollar market for vascular grafts, there's a clear need for improvement. ArtiFex's innovative vascular graft, made of cobalt-chrome and cellulose promotes tissue regeneration, strength, and ensures blood flow without causing clotting or immune reactions.

MLA Diagnostics improves melanoma diagnosis, offering personalized measurement of malignancy levels. Traditional diagnosis often leads to overtreatment or undertreatment, resulting in patient distress or undetected cancer progression. By analyzing methylation, our test provides accurate prognosis, enabling tailored treatment plans and saving lives. With the melanoma therapeutics market on the rise, our innovative solution is poised to make a significant impact, improve patient outcomes and create opportunities.

RetinaCheck has developed automated diabetic retinopathy screening software that combines brain-inspired geometric methods and CNNs to analyse fundus camera images. It targets the large undetected burden of early diabetic eye damage in China, where roughly 11.6% of the population has type 2 diabetes and retinopathy is the leading cause of new working-age blindness. The software is now widely used across the country.

Sansepsis is a new treatment for sepsis, a serious condition causing many hospital deaths. Developed by Sanquin, a top blood bank in Europe, it uses a special filtering technology called apheresis to remove harmful pathogens from the blood. This innovative approach aims to improve patient outcomes and reduce the high costs associated with treating sepsis, offering hope for better management of this deadly condition.